Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)
ABSTRACT Background Treatment with sphingosine‐1‐phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD). Objectives We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD. Methods S1P concentrations we...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2021-09, Vol.36 (9), p.2178-2182 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2182 |
|---|---|
| container_issue | 9 |
| container_start_page | 2178 |
| container_title | Movement disorders |
| container_volume | 36 |
| creator | Schwedhelm, Edzard Englisch, Catrin Niemann, Louisa Lezius, Susanne Lucadou, Mirjam Marmann, Kristina Böger, Rainer Peine, Sven Daum, Günter Gerloff, Christian Choe, Chi‐un |
| description | ABSTRACT
Background
Treatment with sphingosine‐1‐phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).
Objectives
We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.
Methods
S1P concentrations were analyzed with liquid chromatography–tandem mass spectrometry (LC–MS/MS) in serum of 196 PD patients and in 196 age‐ and sex‐matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow‐up data was available from 64 patients (median [interquartile range], 513 [381–677] days).
Results
S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38–2.07) and 1.90 (1.59–2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow‐up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.
Conclusions
Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society |
| doi_str_mv | 10.1002/mds.28652 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000651822600001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2574420954</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4542-1349302b772566d03f230f1afa11f90e932e9f83cfd31e8ac2de4821157d30913</originalsourceid><addsrcrecordid>eNqNkM1OGzEURq2qqKTAoi9QjdQFIBi4_pt4ligpbVWiRoSuLWfmmpgSO9iTVtn1EfqMPEmdJrBD6sKyJZ_7-fMh5B2FMwrAzudtOmOqkuwV6VHJaamY7L8mPVBKlpwquUvepnQHQKmk1RuyywXku1r0iJ4sZs7fhuQ8Pv7-Q_Maz0JazEyHp8UodCEWE_yJ0XWr08L4thjHcBsxJRd84XwxNvGH8yn4w1QMXUKTsDgaXVx_XScNj_fJjjX3CQ-2-x75fvnxZvC5vPr26cvg4qpshBSspFzUHNi032eyqlrglnGw1FhDqa0Ba86wtoo3tuUUlWlYi0Kx_J9-y6GmfI982OQuYnhYYur0XVhGn5_U2YUQDGopMnW8oZoYUopo9SK6uYkrTUGvVeqsUv9Tmdn328TldI7tM_nkLgMnG-AXToNNjUPf4DMGAJWkirEqn2BdUP0_PXCd6bLgQVj6Lo-eb0fdPa5erqxHw8mm-18a1Z6N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574420954</pqid></control><display><type>article</type><title>Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Schwedhelm, Edzard ; Englisch, Catrin ; Niemann, Louisa ; Lezius, Susanne ; Lucadou, Mirjam ; Marmann, Kristina ; Böger, Rainer ; Peine, Sven ; Daum, Günter ; Gerloff, Christian ; Choe, Chi‐un</creator><creatorcontrib>Schwedhelm, Edzard ; Englisch, Catrin ; Niemann, Louisa ; Lezius, Susanne ; Lucadou, Mirjam ; Marmann, Kristina ; Böger, Rainer ; Peine, Sven ; Daum, Günter ; Gerloff, Christian ; Choe, Chi‐un</creatorcontrib><description>ABSTRACT
Background
Treatment with sphingosine‐1‐phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).
Objectives
We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.
Methods
S1P concentrations were analyzed with liquid chromatography–tandem mass spectrometry (LC–MS/MS) in serum of 196 PD patients and in 196 age‐ and sex‐matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow‐up data was available from 64 patients (median [interquartile range], 513 [381–677] days).
Results
S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38–2.07) and 1.90 (1.59–2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow‐up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.
Conclusions
Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.28652</identifier><identifier>PMID: 34008894</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animal models ; biomarker ; Chromatography, Liquid ; Clinical Neurology ; Cognitive ability ; Disease Progression ; Hoehn and Yahr ; Humans ; Life Sciences & Biomedicine ; Liquid chromatography ; Lysophospholipids ; Mass spectroscopy ; Mental Status and Dementia Tests ; Movement disorders ; Neurodegenerative diseases ; Neuroprotection ; Neurosciences & Neurology ; Parkinson Disease - drug therapy ; Parkinson's disease ; Patients ; Science & Technology ; Severity of Illness Index ; Sphingosine - analogs & derivatives ; sphingosine‐1‐phosphate ; Tandem Mass Spectrometry ; UPDRS</subject><ispartof>Movement disorders, 2021-09, Vol.36 (9), p.2178-2182</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society</rights><rights>2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>10</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000651822600001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4542-1349302b772566d03f230f1afa11f90e932e9f83cfd31e8ac2de4821157d30913</citedby><cites>FETCH-LOGICAL-c4542-1349302b772566d03f230f1afa11f90e932e9f83cfd31e8ac2de4821157d30913</cites><orcidid>0000-0002-9154-8439</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.28652$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.28652$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,39267,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34008894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwedhelm, Edzard</creatorcontrib><creatorcontrib>Englisch, Catrin</creatorcontrib><creatorcontrib>Niemann, Louisa</creatorcontrib><creatorcontrib>Lezius, Susanne</creatorcontrib><creatorcontrib>Lucadou, Mirjam</creatorcontrib><creatorcontrib>Marmann, Kristina</creatorcontrib><creatorcontrib>Böger, Rainer</creatorcontrib><creatorcontrib>Peine, Sven</creatorcontrib><creatorcontrib>Daum, Günter</creatorcontrib><creatorcontrib>Gerloff, Christian</creatorcontrib><creatorcontrib>Choe, Chi‐un</creatorcontrib><title>Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)</title><title>Movement disorders</title><addtitle>MOVEMENT DISORD</addtitle><addtitle>Mov Disord</addtitle><description>ABSTRACT
Background
Treatment with sphingosine‐1‐phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).
Objectives
We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.
Methods
S1P concentrations were analyzed with liquid chromatography–tandem mass spectrometry (LC–MS/MS) in serum of 196 PD patients and in 196 age‐ and sex‐matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow‐up data was available from 64 patients (median [interquartile range], 513 [381–677] days).
Results
S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38–2.07) and 1.90 (1.59–2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow‐up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.
Conclusions
Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society</description><subject>Animal models</subject><subject>biomarker</subject><subject>Chromatography, Liquid</subject><subject>Clinical Neurology</subject><subject>Cognitive ability</subject><subject>Disease Progression</subject><subject>Hoehn and Yahr</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Liquid chromatography</subject><subject>Lysophospholipids</subject><subject>Mass spectroscopy</subject><subject>Mental Status and Dementia Tests</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroprotection</subject><subject>Neurosciences & Neurology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Science & Technology</subject><subject>Severity of Illness Index</subject><subject>Sphingosine - analogs & derivatives</subject><subject>sphingosine‐1‐phosphate</subject><subject>Tandem Mass Spectrometry</subject><subject>UPDRS</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkM1OGzEURq2qqKTAoi9QjdQFIBi4_pt4ligpbVWiRoSuLWfmmpgSO9iTVtn1EfqMPEmdJrBD6sKyJZ_7-fMh5B2FMwrAzudtOmOqkuwV6VHJaamY7L8mPVBKlpwquUvepnQHQKmk1RuyywXku1r0iJ4sZs7fhuQ8Pv7-Q_Maz0JazEyHp8UodCEWE_yJ0XWr08L4thjHcBsxJRd84XwxNvGH8yn4w1QMXUKTsDgaXVx_XScNj_fJjjX3CQ-2-x75fvnxZvC5vPr26cvg4qpshBSspFzUHNi032eyqlrglnGw1FhDqa0Ba86wtoo3tuUUlWlYi0Kx_J9-y6GmfI982OQuYnhYYur0XVhGn5_U2YUQDGopMnW8oZoYUopo9SK6uYkrTUGvVeqsUv9Tmdn328TldI7tM_nkLgMnG-AXToNNjUPf4DMGAJWkirEqn2BdUP0_PXCd6bLgQVj6Lo-eb0fdPa5erqxHw8mm-18a1Z6N</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Schwedhelm, Edzard</creator><creator>Englisch, Catrin</creator><creator>Niemann, Louisa</creator><creator>Lezius, Susanne</creator><creator>Lucadou, Mirjam</creator><creator>Marmann, Kristina</creator><creator>Böger, Rainer</creator><creator>Peine, Sven</creator><creator>Daum, Günter</creator><creator>Gerloff, Christian</creator><creator>Choe, Chi‐un</creator><general>John Wiley & Sons, Inc</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-9154-8439</orcidid></search><sort><creationdate>202109</creationdate><title>Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)</title><author>Schwedhelm, Edzard ; Englisch, Catrin ; Niemann, Louisa ; Lezius, Susanne ; Lucadou, Mirjam ; Marmann, Kristina ; Böger, Rainer ; Peine, Sven ; Daum, Günter ; Gerloff, Christian ; Choe, Chi‐un</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4542-1349302b772566d03f230f1afa11f90e932e9f83cfd31e8ac2de4821157d30913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animal models</topic><topic>biomarker</topic><topic>Chromatography, Liquid</topic><topic>Clinical Neurology</topic><topic>Cognitive ability</topic><topic>Disease Progression</topic><topic>Hoehn and Yahr</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Liquid chromatography</topic><topic>Lysophospholipids</topic><topic>Mass spectroscopy</topic><topic>Mental Status and Dementia Tests</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroprotection</topic><topic>Neurosciences & Neurology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Science & Technology</topic><topic>Severity of Illness Index</topic><topic>Sphingosine - analogs & derivatives</topic><topic>sphingosine‐1‐phosphate</topic><topic>Tandem Mass Spectrometry</topic><topic>UPDRS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwedhelm, Edzard</creatorcontrib><creatorcontrib>Englisch, Catrin</creatorcontrib><creatorcontrib>Niemann, Louisa</creatorcontrib><creatorcontrib>Lezius, Susanne</creatorcontrib><creatorcontrib>Lucadou, Mirjam</creatorcontrib><creatorcontrib>Marmann, Kristina</creatorcontrib><creatorcontrib>Böger, Rainer</creatorcontrib><creatorcontrib>Peine, Sven</creatorcontrib><creatorcontrib>Daum, Günter</creatorcontrib><creatorcontrib>Gerloff, Christian</creatorcontrib><creatorcontrib>Choe, Chi‐un</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwedhelm, Edzard</au><au>Englisch, Catrin</au><au>Niemann, Louisa</au><au>Lezius, Susanne</au><au>Lucadou, Mirjam</au><au>Marmann, Kristina</au><au>Böger, Rainer</au><au>Peine, Sven</au><au>Daum, Günter</au><au>Gerloff, Christian</au><au>Choe, Chi‐un</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)</atitle><jtitle>Movement disorders</jtitle><stitle>MOVEMENT DISORD</stitle><addtitle>Mov Disord</addtitle><date>2021-09</date><risdate>2021</risdate><volume>36</volume><issue>9</issue><spage>2178</spage><epage>2182</epage><pages>2178-2182</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>ABSTRACT
Background
Treatment with sphingosine‐1‐phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).
Objectives
We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.
Methods
S1P concentrations were analyzed with liquid chromatography–tandem mass spectrometry (LC–MS/MS) in serum of 196 PD patients and in 196 age‐ and sex‐matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow‐up data was available from 64 patients (median [interquartile range], 513 [381–677] days).
Results
S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38–2.07) and 1.90 (1.59–2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow‐up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.
Conclusions
Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34008894</pmid><doi>10.1002/mds.28652</doi><orcidid>https://orcid.org/0000-0002-9154-8439</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2021-09, Vol.36 (9), p.2178-2182 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_webofscience_primary_000651822600001 |
| source | MEDLINE; Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Animal models biomarker Chromatography, Liquid Clinical Neurology Cognitive ability Disease Progression Hoehn and Yahr Humans Life Sciences & Biomedicine Liquid chromatography Lysophospholipids Mass spectroscopy Mental Status and Dementia Tests Movement disorders Neurodegenerative diseases Neuroprotection Neurosciences & Neurology Parkinson Disease - drug therapy Parkinson's disease Patients Science & Technology Severity of Illness Index Sphingosine - analogs & derivatives sphingosine‐1‐phosphate Tandem Mass Spectrometry UPDRS |
| title | Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T01%3A21%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sphingosine%E2%80%901%E2%80%90Phosphate,%20Motor%20Severity,%20and%20Progression%20in%20Parkinson's%20Disease%20(MARK%E2%80%90PD)&rft.jtitle=Movement%20disorders&rft.au=Schwedhelm,%20Edzard&rft.date=2021-09&rft.volume=36&rft.issue=9&rft.spage=2178&rft.epage=2182&rft.pages=2178-2182&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.28652&rft_dat=%3Cproquest_webof%3E2574420954%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2574420954&rft_id=info:pmid/34008894&rfr_iscdi=true |